SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of CytoDyn Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 17, 2021 - CYDY

May 16, 2021 3:29 PM EDT | Source: Levi & Korsinsky, LLP

New York, New York--(Newsfile Corp. - May 16, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of CytoDyn Inc. ("CytoDyn") (OTCQB: CYDY) between March 27, 2020 and March 9, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Washington. To get more information go to:

https://www.zlk.com/pslra-1/cytodyn-inc-loss-submission-form?prid=15917&wire=5

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7091/84247_170422_logo.jpg

CytoDyn Inc. NEWS - CYDY NEWS

CASE DETAILS: The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: CytoDyn securities were actively traded over the counter (OTC) in the United States. While the exact number of Class members is unknown to Plaintiff at this time and can be ascertained only through appropriate discovery, Plaintiff believes that there are hundreds or thousands of members in the proposed Class. Record owners and other members of the Class may be identified from records maintained by CytoDyn or its transfer agent and/or OTC Markets and may be notified of the pendency of this action by mail, using the form of notice similar to that customarily used in securities class actions.

WHAT THIS MEANS TO SHAREHOLDERS: If you suffered a loss in CytoDyn you have until May 17, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you purchased CytoDyn securities during the Class Period date OF between March 27, 2020 and March 9, 2021, you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

HOW TO JOIN THE CLASS ACTION: Complete this brief submission form https://www.zlk.com/pslra-1/cytodyn-inc-loss-submission-form?prid=15917&wire=5 or call 212-363-7500 to speak to Joseph E. Levi, Esq. to discuss this case.

WHY LEVI & KORSINSKY: Levi & Korsinsky have a proven track record of winning cases worth hundreds of millions of dollars for shareholders over a 20-year period. We represent and fight for shareholders who have been wronged by Corporations.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The Firm's Founding Partners, Joseph Levi and Eduard Korsinsky have been representing shareholders and institutional clients for almost 20 years and have achieved remarkable results for clients in the U.S. and internationally. The firm, with more than 90 employees, is committed to fostering, cultivating and preserving a culture of diversity, equity and inclusion for employees and those that we represent. Our attorneys have extensive expertise representing investors in securities litigation with a track record of recovering hundreds of millions of dollars in cases. Levi & Korsinsky was ranked in Institutional Shareholder Services' ("ISS") SCAS Top 50 Report for 7 years in a row as a top securities litigation firm in the United States. The SCAS Top 50 Report identifies the top plaintiffs' securities law firms in the country, and year after year, ISS has recognized Levi & Korsinsky as a leading firm in the area of securities class action litigation.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/84247

info